Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
23.06
-0.10 (-0.43%)
Nov 18, 2025, 3:00 PM CST
Chengdu Olymvax Biopharmaceuticals Company Description
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China.
The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b.
It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine.
The company was founded in 2009 and is based in Chengdu, China.
Chengdu Olymvax Biopharmaceuticals Inc.
| Country | China |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 470 |
| CEO | Shaowen Fan |
Contact Details
Address: No. 99 Tianxin Road Chengdu, 611731 China | |
| Phone | 86 28 6936 1111 |
| Website | olymvax.com |
Stock Details
| Ticker Symbol | 688319 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000051H8 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shaowen Fan | Chairman of the Board and GM |
| Yong Tan | Chief Financial Officer and Deputy GM |
| Aimin Chen | Director and Deputy GM |
| Wei Wu | Secretary of the Board and Deputy GM |
| Xingyao Qin | Accounting supervisor |